These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 28178378

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway.
    Tao NN, Zhou HZ, Tang H, Cai XF, Zhang WL, Ren JH, Zhou L, Chen X, Chen K, Li WY, Liu B, Yang QX, Cheng ST, Huang LX, Huang AL, Chen J.
    Oncotarget; 2016 Aug 02; 7(31):50117-50130. PubMed ID: 27367026
    [Abstract] [Full Text] [Related]

  • 4. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.
    Prieto-Domínguez N, Ordóñez R, Fernández A, Méndez-Blanco C, Baulies A, Garcia-Ruiz C, Fernández-Checa JC, Mauriz JL, González-Gallego J.
    J Pineal Res; 2016 Oct 02; 61(3):396-407. PubMed ID: 27484637
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells.
    Lin YT, Chao CC.
    Oncotarget; 2015 Nov 17; 6(36):38999-9017. PubMed ID: 26517516
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
    Honma Y, Harada M.
    Exp Cell Res; 2013 Aug 15; 319(14):2166-78. PubMed ID: 23727131
    [Abstract] [Full Text] [Related]

  • 12. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
    Zhai B, Hu F, Yan H, Zhao D, Jin X, Fang T, Pan S, Sun X, Xu L.
    PLoS One; 2015 Aug 15; 10(9):e0138485. PubMed ID: 26381511
    [Abstract] [Full Text] [Related]

  • 13. Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation.
    Yan Y, Wang L, He J, Liu P, Lv X, Zhang Y, Xu X, Zhang L, Zhang Y.
    Biomed Pharmacother; 2017 Apr 15; 88():395-402. PubMed ID: 28122304
    [Abstract] [Full Text] [Related]

  • 14. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L.
    Hepatology; 2013 May 15; 57(5):1847-57. PubMed ID: 23299930
    [Abstract] [Full Text] [Related]

  • 15. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D, Zhai B, He C, Tan G, Jiang X, Pan S, Dong X, Wei Z, Ma L, Qiao H, Jiang H, Sun X.
    Cell Signal; 2014 May 15; 26(5):1030-9. PubMed ID: 24486412
    [Abstract] [Full Text] [Related]

  • 16. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 17. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
    Ishijima N, Kanki K, Shimizu H, Shiota G.
    Cancer Sci; 2015 May 06; 106(5):567-75. PubMed ID: 25683251
    [Abstract] [Full Text] [Related]

  • 18. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL.
    Clin Cancer Res; 2009 Sep 15; 15(18):5820-8. PubMed ID: 19737956
    [Abstract] [Full Text] [Related]

  • 19. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI, Tai WT, Hung MH, Tsai MH, Chen MH, Chang MJ, Shiau CW, Chen KF.
    Cancer Lett; 2016 Feb 28; 371(2):205-13. PubMed ID: 26679051
    [Abstract] [Full Text] [Related]

  • 20. Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma.
    Nojiri K, Sugimoto K, Shiraki K, Tameda M, Inagaki Y, Ogura S, Kasai C, Kusagawa S, Yoneda M, Yamamoto N, Takei Y, Nobori T, Ito M.
    Int J Oncol; 2013 Jan 28; 42(1):101-8. PubMed ID: 23123700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.